COMMUNIQUÉS West-GlobeNewswire

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
27/04/2026
COPENHAGEN, Denmark, April 27, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on March 12, 2026, under which the Company will repurchase shares for an amount up [...]
OSE Immunotherapeutics se félicite de l'octroi de la désignation de médicament orphelin par la FDA du pegrizeprument (VEL-101) pour la prévention du rejet d’organe dans la transplantation cardiaque
27/04/2026
Nantes, le 27 avril, 7h30 CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo : OSE) se félicite aujourd’hui de l’annonce faite par son partenaire Veloxis Pharmaceuticals, Inc., rapportant que la U.S. Food and [...]
Dark Horse Consulting Group and Porton Advanced Announce Memorandum of Understanding Providing a Streamlined Path to Conducting IITs in China
27/04/2026
WALNUT CREEK, Calif. and SUZHOU, China, April 26, 2026 (GLOBE NEWSWIRE) -- Dark Horse Consulting Group (“DHCG” or “the Group”), a leader in strategic and operational biotherapeutics consulting, and Porton Advanced, a [...]
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) for Prevention of Organ Rejection in Heart Transplant Patients
27/04/2026
Nantes, France, April 27, 2026 – 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today welcomes the announcement by its partner Veloxis Pharmaceuticals, Inc. that the U.S. Food and Drug [...]
Santhera Receives Positive CHMP Opinion to Expand AGAMREE® (vamorolone) Use in Pediatric DMD Patients Aged Two and Older in the EU
27/04/2026
Pratteln, Switzerland, April 27, 2026 – Santhera Pharmaceuticals (SIX: SANN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive [...]
Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria
27/04/2026
Significant improvements as early as Week 1, favorable safety profile and no liver safety concerns in REMIX 1 & 2 studies of highly selective, oral BTKi 1 Rhapsido recommended in 2026 International Urticaria [...]
C3 Davos of Healthcare™ Silicon Valley Summit Opens Tomorrow in Sunnyvale with KFSH
26/04/2026
SUNNYVALE, Calif., April 26, 2026 (GLOBE NEWSWIRE) -- The C3 Davos of Healthcare™ Silicon Valley Summit will begin tomorrow at the Plug and Play Tech Center in Sunnyvale, California, under the theme “Healthtech [...]
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026
26/04/2026
MENLO PARK, Calif., April 26, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the [...]
HeroUp Claims Evaluated: Investigating the Supplement Facts About Hero Up Capsules for Hardero Male Enhancement Support
26/04/2026
A 2026 overview of HeroUp's proprietary blend, supplement facts, 800 mg ingredient profile, pricing, and 180-day guarantee Lakeland, FL, April 25, 2026 (GLOBE NEWSWIRE) -- This content contains affiliate links. If a [...]
HealthRX Blood Support Claims Evaluated: The Health RX Blood Pressure Optimizer Formula Under Investigation
25/04/2026
A 2026 informational overview of the Health RX Blood Optimizer formula, ingredient research context, pricing structure, and what consumers should verify before purchasing New York, NY, April 25, 2026 (GLOBE NEWSWIRE [...]
Quad ED Under Investigation: Safe Clinician-Prescribed ED Medication Using Sildenafil, Tadalafil, Vardenafil and Apomorphine for Men
26/04/2026
A consumer-informational overview addressing common search questions about the Quad 4-in-1 compounded sublingual ED formulation — how clinician-prescribed Sildenafil, Tadalafil, Vardenafil, and Apomorphine work together [...]
KFSH Advances Precision Surgery Through In-House 3D Printing Program
25/04/2026
RIYADH, Saudi Arabia, April 25, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH) is redefining surgical precision through an advanced in-house 3D printing program that is reshaping how [...]
Alpha Labs Male Enhancement Gummies Claims Evaluated: The AlphaLabs ED Gummy for Men Under Investigation
25/04/2026
A 2026 informational overview of Alpha Labs Male Enhancement Gummies covering ingredient research context, how the brand presents its men's vitality formula, pricing details, and key considerations for men exploring ED [...]
AEON Biopharma Sets Annual Shareholder Meeting
24/04/2026
- Annual Shareholder Meeting to be held at 10:00 am PT on June 17, 2026 - IRVINE, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical [...]
Biotech startup Plopii Files US Patent on the Next-Generation Headache Pill
24/04/2026
Brooklyn biotech files 40-claim patent application covering a new active-ingredient combination for over-the-counter headache relief NEW YORK, April 24, 2026 (GLOBE NEWSWIRE) -- Plopii , a Brooklyn-based biotechnology [...]
Crescent Biopharma Announces Grants of Inducement Awards
24/04/2026
WALTHAM, Mass., April 24, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma , Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies [...]
ForLife and Oakmed Ltd. to Become Unora GmbH and Unora Healthcare Ltd Effective May 1, 2026
24/04/2026
Healthcare products company unveils new brand identity and introduces Silkura, a revolutionary silicone-based ostomy pouch BERLIN, April 24, 2026 (GLOBE NEWSWIRE) -- ForLife Produktions- und Vertriebsgesellschaft für [...]
Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim
24/04/2026
Ruling preserves current contracted royalty rates and rejects Tesaro’s request for any royalty reduction Trial to adjudicate Anaptys’ contract claims and right to seek reversion of Jemperli against Tesaro/GSK is [...]
Communiqué de presse : Sanofi place 2,3 milliard d’euros d’emprunts obligataires
24/04/2026
Sanofi place 2,3 milliard d’euros d’emprunts obligataires Paris, 24 avril 2026 - Sanofi annonce avoir placé avec succès une émission obligataire en 3 tranches (les « obligations ») pour un montant de 2,3 milliards d’ [...]

Pages